Background: Chronic kidney disease (CKD) is associated to a higher stroke risk. Anemia is a common consequence of CKD, and is also a possible risk factor for cerebrovascular diseases. The purpose ...

Anemia is common in patients who have both heart failure and chronic kidney disease, and there is an association between anemia and progression of both diseases. The main causes of anemia are ...

AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to ...

Chronic kidney disease may also be identified when it leads to one of its recognized complications, such as cardiovascular disease, anemia or pericarditis. There is no specific treatment ...

AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia drug in the ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

The following is a summary of “Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study,” published in the February 2025 issue of BMC Primary Care by ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

But taking care of your mental health can have a positive effect on your outlook with kidney disease. Chronic kidney disease (CKD) is a lifelong condition and requires medical treatment.

A recent modeling study has identified risk factors predictive of good and bad outcomes in non-diabetic CKD, such as gender, race, and albuminuria.